Core Viewpoint - 来凯医药-B (02105) has seen a significant stock price increase following the announcement of a successful placement of 36 million shares at HKD 16.30 per share, raising approximately HKD 577 million for research and development purposes related to its ActRII product portfolio [1] Group 1: Financial Performance - The stock price rose over 8% to HKD 13.9, with a trading volume of HKD 34.24 million [1] - The net proceeds from the share placement are intended for R&D expenditures for the ActRII product portfolio, ongoing preclinical candidate drug development, and general corporate purposes [1] Group 2: Product Development - The ActRII pathway is identified as a key muscle regulation pathway, attracting interest from multiple multinational pharmaceutical companies [1] - The company has three muscle enhancement products centered around the ActRII pathway, with LAE102 having completed the SAD study and currently undergoing MAD studies [1] - A clinical collaboration agreement with Eli Lilly for LAE102 is set for November 2024, where Eli Lilly will conduct Phase I clinical trials in the U.S. and cover related costs, while the company retains global rights to LAE102 [1] - The company plans to submit clinical trial applications for LAE103 and LAE123 in Q2 2025 and Q3 2025, respectively [1]
来凯医药-B早盘涨超7% 公司完成配售净筹约5.77亿港元 拟用于推进ActRII产品组合开发